An international study led by Memorial Sloan-Kettering found that pazopanib (Votrient^®) controls cancer as effectively as sunitinib (Sutent^®) while improving patients’ quality of life.

In an eagerly awaited study, Memorial Sloan-Kettering researchers report on the molecular structure of mTOR, a protein commonly mutated in cancer.

Charles Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.

A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases.

Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.

Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers.

Recent findings by Memorial Sloan-Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor.